MLYS News - Candlesense

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

(NASDAQ:MLYS) RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hyp...

How might the full exercise of the underwriters’ option to purchase additional shares impact the stock’s price and trading volume in the short term? What is the intended allocation of the proceeds and how will it influence upcoming clinical milestones or partnership opportunities? How will the $287.5 million capital raise affect Mineralys’ cash runway and dilution?

Capital

6 days ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

(NASDAQ:MLYS) RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hyp...

How does this financing round compare to recent capital raises by peers in the hypertension/CKD space and what does it imply for the stock’s valuation and trading volume? What dilution impact will the upsized offering and the underwriters' 30‑day option have on existing shareholders' ownership percentages? How will the $250 million capital raise affect Mineralys Therapeutics' cash runway and timeline to key clinical milestones?

Offering

8 days ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

(NASDAQ:MLYS) RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hyp...

How does this offering compare to recent capital raises by comparable biotech peers in terms of size, pricing, and market reception? What are the intended uses for the offering proceeds and how will they impact the company's clinical development timeline? How will the $175 million equity raise affect Mineralys Therapeutics' share dilution and valuation?

Equity offering

8 days ago